Holen Sie sich die Stockscreener-App
34.05
4.21%
-1.42
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$35.47
Offen:
$35.16
24-Stunden-Volumen:
1.11M
Relative Volume:
0.38
Marktkapitalisierung:
$5.39B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-309.55
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
+1.73%
1M Leistung:
-8.10%
6M Leistung:
-1.66%
1J Leistung:
+104.68%
1-Tages-Spanne:
$33.67
$35.18
1-Wochen-Bereich:
$33.11
$35.62
52-Wochen-Spanne:
$15.16
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
33.98 | 5.30B | 264.79M | -14.36M | -28.11M | -0.11 |
|
ONC
Beigene Ltd Adr
|
236.04 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.27 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3064 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.87 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.64 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture - simplywall.st
Investor Calendar Invites You to the TG Therapeutics, Inc. Third Quarter 2016 Earnings Conference Call and Webcast Live on Monday, November 7, 2016 - ACCESS Newswire
(TGTX) Long Term Investment Analysis - news.stocktradersdaily.com
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook - MSN
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
TG Therapeutics raises 2025 guidance to $560M, driven by BRIUMVI adoption - MSN
TG Therapeutics stock sinks on profit miss - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Str - GuruFocus
Jefferies maintains Buy on TGTX stock with $46 target By Investing.com - Investing.com Nigeria
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... - Yahoo Finance
TG Therapeutics Inc (TGTX) Q1 2025 Earnings Call Highlights: Strong BRIUMVI Sales and Increased ... By GuruFocus - Investing.com Canada
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook By Stocktwits - Investing.com India
TG Therapeutics: Q1 Earnings Snapshot - MySA
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show - Benzinga
Why TG Therapeutics Stock Was Tumbling Today - AOL.com
TGTX Stock Dips Despite Surging Revenue and Profitability - GuruFocus
Jefferies maintains Buy on TGTX stock with $46 target - Investing.com
TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges (TGTX) - Seeking Alpha
TG Therapeutics (TGTX) Stock Falls After Earnings Miss Despite Raised Guidance - GuruFocus
TG Therapeutics stock sinks on profit miss (TGTX:NASDAQ) - Seeking Alpha
Strong Q1 Performance for TG Therapeutics (TGTX) with BRIUMVI Growth - GuruFocus
Earnings call transcript: TG Therapeutics misses Q1 2025 EPS forecast, shares dip - Investing.com
TG Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic - MSN
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates - Yahoo Finance
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance - GlobeNewswire
TG Therapeutics (TGTX) Misses Q1 EPS Estimates, Raises 2025 Reve - GuruFocus
TG Therapeutics Inc (TGTX) Reports Q1 2025 Revenue of $119.7 Million, Surpassing Estimates - GuruFocus
TG Therapeutics' Q1 Swings to Net Income, Revenue Rises; Full-Year 2025 BRIUMVI Revenue Guidance Updated - marketscreener.com
TG Therapeutics Reports First Quarter 2025 Financial Results - TradingView
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance | TGTX Stock News - GuruFocus
TG Therapeutics Q1 revenue beats estimates, stock edges higher By Investing.com - Investing.com Canada
TG Therapeutics Q1 revenue beats estimates, stock edges higher - Investing.com
TGTX Surpasses Revenue Expectations with Strong Q1 Performance | TGTX Stock News - GuruFocus
Earnings Flash (TGTX) TG Therapeutics Posts Q1 EPS $0.03, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (TGTX) TG Therapeutics Reports Q1 Revenue $120.9M, vs. FactSet Est of $117.9M - marketscreener.com
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
TG Therapeutics Earnings Loom With Stock (NASDAQ: TGTX) Outperforming Market - AskTraders.com
When (TGTX) Moves Investors should Listen - news.stocktradersdaily.com
TG Therapeutics (TGTX) Schedules Q1 2025 Earnings Call - GuruFocus
TG Therapeutics (TGTX) Poised for Major Earnings Growth in Q1 - GuruFocus
TG Therapeutics stock soars to 52-week high of $45.28 By Investing.com - Investing.com India
TG Therapeutics stock soars to 52-week high of $45.28 - Investing.com
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth - Yahoo Finance
TG Therapeutics to Host Conference Call on First Quarter 2025 Fi - GuruFocus
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update | TGTX Stock News - GuruFocus
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):